Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Stockholm - Delayed Quote SEK

Hamlet BioPharma AB ser. B (HAMLET-B.ST)

Compare
4.3500
+0.0500
+(1.16%)
At close: February 28 at 5:29:42 PM GMT+1

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Dr. Catharina Svanborg M.D. Founder, CEO & Director -- -- 1949
Mr. Jakob Testad Finance Director -- -- --
Mr. Mats Persson Executive Officer -- -- 1961

Hamlet BioPharma AB ser. B

BMC D10
Klinikgatan 32
Lund, 222 42
Sweden
46 40 12 25 00 https://www.hamletpharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
7

Description

Hamlet BioPharma AB (publ) engages in the development of drugs for the treatment and prevention of cancer in Sweden. It is developing HAMLET, a tumoricidal protein-lipid complex formed by two generally regarded as safe (GRAS) molecules found in human milk for various oncology markets, including colon, bladder, and cervix cancers, as well as primary or metastatic brain tumors. The company's products under development include Alpha1H for the treatment of bladder cancer and brain tumors; and BAMLET for the treatment of colon and oral cancer. The company was formerly known as Hamlet Pharma AB (publ) and changed its name to Hamlet BioPharma AB (publ) in August 2023. Hamlet BioPharma AB (publ) was incorporated in 1999 and is based in Lund, Sweden. Hamlet BioPharma AB (publ) is a subsidiary of Linnane Pharma AB.

Corporate Governance

Hamlet BioPharma AB ser. B’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

O33.F Glycorex Transplantation AB (publ)
0.2030
-5.58%
 
DMYD-B.ST Diamyd Medical AB (publ)
10.00
-36.71%
 
ATORX.ST Alligator Bioscience AB (publ)
0.0683
-36.76%
 
FARON.HE Faron Pharmaceuticals Oy
2.0100
-0.99%
 
PRLD Prelude Therapeutics Incorporated
0.7590
+1.88%
 
TRVI Trevi Therapeutics, Inc.
4.5200
+0.44%
 
RPTX Repare Therapeutics Inc.
1.1800
-1.67%
 
CAMP CAMP4 THERAPEUTICS CORPORATION
4.9100
+30.93%
 
ALDX Aldeyra Therapeutics, Inc.
5.11
-19.40%
 
OSRH OSR Holdings, Inc.
3.0400
-8.43%